NeuroOne Medical Technologies (NMTC) AI Stock Analysis

• Market Cap: $38.61M
• Dividend Yield: N/A
• Average Volume (3M): 532.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: 250.35%
• EPS Growth: 83.06%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.05
• Shares Outstanding: 50,413,147
• 10 Day Avg. Volume: 702,340
• 30 Day Avg. Volume: 532,447
• PEG Ratio: 0.12
• Price to Book (P/B): 5.04
• Price to Sales (P/S): 3.92
• P/FCF Ratio: -12.22
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 3.22
• Enterprise Value/Gross Profit: 5.69
• Enterprise Value/Ebitda: -9.72
• 1Y Price Target: $3.00
• Price Target Upside: 322.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $0.75 ▲(5.35% Upside)

NeuroOne's strong revenue growth and strategic developments are overshadowed by profitability challenges and a negative valuation. The earnings call provided positive insights, but technical indicators and valuation remain concerns.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing market acceptance and demand for NMTC's products, potentially leading to sustained long-term expansion.

Improved Gross Margins

Higher gross margins reflect enhanced operational efficiency, which can improve profitability and provide more resources for innovation and growth.

Strategic Partnerships

Partnerships with established firms like Zimmer Biomet can enhance distribution capabilities and market reach, supporting long-term growth.

Negative Factors

Profitability Challenges

Ongoing net losses highlight profitability challenges, which could hinder reinvestment and growth opportunities if not addressed.

Cash Flow Issues

Negative cash flows suggest liquidity constraints, potentially impacting the company's ability to fund operations and strategic initiatives.

NASDAQ Compliance Challenge

Compliance issues with NASDAQ can affect investor confidence and market perception, posing a risk to the company's stock stability.

NeuroOne Medical Technologies Business Overview & Revenue Model

Company Description

NeuroOne Medical Technologies (NMTC) is a medical device company focused on developing innovative solutions for neurological disorders, specifically targeting conditions such as epilepsy and chronic pain. The company operates within the healthcare sector, primarily specializing in advanced electrode technology and implantable devices designed for brain monitoring and stimulation. NMTC's core products include its ultra-thin and flexible electrode arrays, which are intended to improve the treatment outcomes for patients undergoing neurological procedures.

How the Company Makes Money

NeuroOne Medical Technologies generates revenue primarily through the sale of its medical devices, particularly its electrode technology used in neurosurgical procedures. The company may also earn income from licensing agreements, collaborations with larger medical device firms, and partnerships with research institutions. Additionally, NMTC could benefit from reimbursement models established by healthcare providers for the use of its products in clinical settings. Significant partnerships with hospitals and neurology clinics could further enhance its market reach and contribute to consistent revenue generation.

NeuroOne Medical Technologies Financial Statement Overview

Summary

NeuroOne Medical Technologies is experiencing strong revenue growth, but profitability and cash flow remain significant challenges. The balance sheet is stable with low leverage, but the company needs to improve its operational efficiency to enhance profitability and cash flow.

Income Statement

The company has shown significant revenue growth of 37.24% in the latest year, indicating a positive trajectory. However, profitability remains a concern with negative net profit and EBIT margins, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio, suggesting conservative leverage. However, the negative return on equity indicates that the company is not generating profits from its equity base, which is a concern for investors.

Cash Flow

The company has negative operating and free cash flows, which have shown a decline in growth. The cash flow to net income ratios are unfavorable, indicating cash flow challenges despite revenue growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	9.10M	12.10M	3.45M	1.95M	171.17K	178.15K
Gross Profit	5.14M	8.14M	1.08M	456.52K	-70.79K	-97.75K
EBITDA	-3.01M	-3.01M	-11.84M	-11.76M	-9.91M	-9.80M
Net Income	-3.61M	-3.61M	-12.32M	-11.86M	-10.00M	-9.95M
Balance Sheet
Total Assets	10.79M	10.79M	5.37M	8.10M	12.82M	7.94M
Cash, Cash Equivalents and Short-Term Investments	6.57M	6.57M	1.46M	5.32M	11.14M	6.90M
Total Debt	266.81K	266.81K	260.16K	184.40K	202.90K	315.67K
Total Liabilities	3.71M	3.71M	4.55M	1.85M	3.22M	1.38M
Stockholders Equity	7.07M	7.07M	822.01K	6.25M	9.60M	6.55M
Cash Flow
Free Cash Flow	-2.92M	-2.92M	-11.13M	-13.27M	-7.79M	-8.67M
Operating Cash Flow	-2.84M	-2.84M	-11.01M	-12.89M	-7.52M	-8.60M
Investing Cash Flow	-81.74K	-81.74K	-120.20K	2.65M	-3.24M	-67.08K
Financing Cash Flow	141.42K	141.42K	7.27M	7.40M	12.02M	11.53M

NeuroOne Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Positive. The current price of 0.71 is above the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.72, and below the 200-day MA of 0.75, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.24 is Neutral, neither overbought nor oversold. The STOCH value of 75.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NMTC.

NeuroOne Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	65 Neutral	$62.25M	-20.52	-5.71%	―	-13.79%	-132.21%
ECOR	55 Neutral	$39.02M	-2.72	-337.84%	―	27.90%	1.62%
NMTC	54 Neutral	$38.61M	-9.76	-91.34%	―	250.35%	83.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RBOT	39 Underperform	$13.95M	-0.22	-148.93%	―	―	15.03%
IINN	35 Underperform	$33.71M	-2.05	―	―	―	―

NeuroOne Medical Technologies Corporate Events

NeuroOne Appoints Jason R. Mills to Board

On December 18, 2025, NeuroOne’s board expanded from four to five members and appointed Jason R. Mills as a Class I director, with his committee roles on the Compensation and Nominating & Corporate Governance Committees effective January 1, 2025, a move publicly announced on December 22, 2025. Mills, currently Executive Vice President of Strategy at Penumbra and a former award-winning med-tech equity research analyst, brings deep industry, strategic and capital markets experience that NeuroOne’s leadership believes will support its clinical and corporate objectives and help broaden its reach as it seeks to advance and commercialize its neurological disorder treatment technologies; on the same day, the company also posted an updated corporate presentation to its investor website to support ongoing communications with the market.

NeuroOne Gets Nasdaq Extension for Compliance

On November 4, 2025, NeuroOne Medical Technologies received a 180-day extension from Nasdaq to comply with the minimum bid price requirement of $1.00 per share for its common stock to remain listed. The extension allows the company until May 4, 2026, to address the compliance issue, with no immediate impact on its current Nasdaq listing. Failure to meet the requirement by the deadline could lead to delisting, although the company plans to monitor and address the issue within the given timeframe.

NeuroOne Reports Record Revenue Growth for 2025

On October 6, 2025, NeuroOne Medical Technologies announced a significant increase in their preliminary unaudited product revenue for the fiscal year 2025, reaching a record $9.1 million, a 163% growth from the previous year. This growth is attributed to the expanded use and positive outcomes of their OneRF® Ablation system for epilepsy patients. The company also reported cash and cash equivalents of $6.6 million as of September 30, 2025. The complete financial results are expected in December 2025, and stakeholders are advised to exercise caution as these results are preliminary and subject to adjustments.